资讯
内科
心血管
肿瘤
内分泌
普通内科
消化
呼吸
神经科
传染科
精神心理
肾内科
风湿免疫
血液科
老年医学
外科
头颈外科
胃肠外科
血管外科
肝胆胰外
骨科
普通外科
胸心外科
神经外科
泌尿外科
烧伤科
整形美容
麻醉疼痛
专科科室
罕见病
康复医学
药械
儿科
耳鼻咽喉
口腔科
眼科
政策人文
营养全科
预防公卫
妇产科
中医科
急重症
皮肤性病
影像放射
转化医学
检验病理
护理
热点
临床研究
研究设计
人工智能
智慧医疗
论文基金
医学科普
药物经济
医生集团
职业安全
患者招募
医学科研
公司产业
医学英语
MedSci动态
指南
按科室浏览
肿瘤科
心血管
传染科
妇产科
神经科
儿科
呼吸
内分泌科
血液科
消化
更多科室
工具
临床工具
临床指南
医学计算与公式
ICD-10/ICD-11疾病编码
医讯达
直播
话题
公开课
精品课
科研工具
期刊数据库查询
期刊智能选择
全球基金查询
文献查询
SCI写作宝典
生物医药大词典
其他工具
下载App使用方便更快捷
Medsci 梅斯搜索
公开课
精品课
服务
科研数智化
直播,公开课与精品课
科研加速器
研究者发起的临床研究(IIS)支持
真实世界研究解决方案
药物经济学
医保准入事务
研究方案设计
数据库建立与管理
药物警戒(PV)
真实世界研究执行
数据统计分析
数字化学术传播解决方案
多渠道营销(MCM)
产品医学策略
学术传播(APO)
其它
积分商城
FAQS
#适应症#
219篇内容 | 3049人围观
关注话题
话题活跃用户
#
插入话题
插入图片
评论
最新
最热
GetTopicDetailResponse(id=554d94e13ae, topicName=适应症, introduction=适应症, content=null, image=null, comments=219, allHits=3049, url=https://h5.medsci.cn/topic?id=94713, type=1, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=11412, tagList=[TagDto(tagId=11412, tagName=适应症)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=1336682, encodeId=a1071336682b9, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=强生抗癌药Imbruvica新适应症获FDA批准, objectType=article, longId=30690, objectId=db57306904b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=db57306904b, replyNumber=0, likeNumber=65, createdTime=2014-02-18, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=db57306904b, moduleTitle=强生抗癌药Imbruvica新适应症获FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=db57306904b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336681, encodeId=ccf9133668107, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=强生拜瑞妥(Xarelto)ACS适应症遭FDA委员会否决, objectType=article, longId=29560, objectId=299929560b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=299929560b7, replyNumber=0, likeNumber=68, createdTime=2014-01-19, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=299929560b7, moduleTitle=强生拜瑞妥(Xarelto)ACS适应症遭FDA委员会否决, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=299929560b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336680, encodeId=3e981336680e7, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=FDA对强生拜瑞妥(Xarelto)ACS适应症持谨慎态度, objectType=article, longId=29502, objectId=cad6295023e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cad6295023e, replyNumber=0, likeNumber=80, createdTime=2014-01-18, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cad6295023e, moduleTitle=FDA对强生拜瑞妥(Xarelto)ACS适应症持谨慎态度, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cad6295023e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336679, encodeId=c92113366e921, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=拜耳多吉美(Nexavar)新适应症用于分化型甲状腺癌获FDA批准, objectType=article, longId=27071, objectId=93e42e071ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=93e42e071ee, replyNumber=0, likeNumber=63, createdTime=2013-11-27, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=93e42e071ee, moduleTitle=拜耳多吉美(Nexavar)新适应症用于分化型甲状腺癌获FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=93e42e071ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336678, encodeId=10e313366e80f, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=ACC/AHA 新胆固醇治疗指南被指扩大了他汀类药物的适应症人群, objectType=article, longId=26764, objectId=f11c26e6465, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f11c26e6465, replyNumber=0, likeNumber=59, createdTime=2013-11-21, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f11c26e6465, moduleTitle=ACC/AHA 新胆固醇治疗指南被指扩大了他汀类药物的适应症人群, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f11c26e6465)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336677, encodeId=306113366e7c7, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=勃林格殷格翰向欧盟提交tiotropium Respimat®扩大适应症申请, objectType=article, longId=26620, objectId=34aa26620b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=34aa26620b7, replyNumber=0, likeNumber=59, createdTime=2013-11-16, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=34aa26620b7, moduleTitle=勃林格殷格翰向欧盟提交tiotropium Respimat®扩大适应症申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=34aa26620b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336676, encodeId=ea7413366e6b3, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=FDA批准阿维莫泮用于术后加速恢复胃肠道功能的新适应症, objectType=article, longId=25793, objectId=59ee25e93ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=59ee25e93ed, replyNumber=0, likeNumber=67, createdTime=2013-10-26, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=59ee25e93ed, moduleTitle=FDA批准阿维莫泮用于术后加速恢复胃肠道功能的新适应症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=59ee25e93ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336675, encodeId=89a913366e52a, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=葛兰素史克Revolade新适应症获欧盟批准, objectType=article, longId=25020, objectId=cd2925020ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cd2925020ce, replyNumber=0, likeNumber=62, createdTime=2013-09-28, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cd2925020ce, moduleTitle=葛兰素史克Revolade新适应症获欧盟批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cd2925020ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336674, encodeId=5ab313366e440, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=拜耳向EMA提交Stivarga治疗GIST新适应症申请, objectType=article, longId=24123, objectId=e08c2412394, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e08c2412394, replyNumber=0, likeNumber=81, createdTime=2013-09-11, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e08c2412394, moduleTitle=拜耳向EMA提交Stivarga治疗GIST新适应症申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e08c2412394)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336673, encodeId=bc0a13366e3a9, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=拜耳Eylea新适应症获欧盟批准, objectType=article, longId=23541, objectId=af4d2354129, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=af4d2354129, replyNumber=0, likeNumber=92, createdTime=2013-09-01, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=af4d2354129, moduleTitle=拜耳Eylea新适应症获欧盟批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=af4d2354129)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336672, encodeId=18fd13366e289, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=拜耳Stivarga新适应症获日本批准, objectType=article, longId=23240, objectId=18f9232401a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=18f9232401a, replyNumber=0, likeNumber=69, createdTime=2013-08-23, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=18f9232401a, moduleTitle=拜耳Stivarga新适应症获日本批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=18f9232401a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336671, encodeId=8c2c13366e1c2, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=葛兰素史克Tyberb新适应症获欧盟批准, objectType=article, longId=23132, objectId=a7b72313238, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a7b72313238, replyNumber=0, likeNumber=72, createdTime=2013-08-21, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a7b72313238, moduleTitle=葛兰素史克Tyberb新适应症获欧盟批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a7b72313238)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336670, encodeId=f4a913366e04d, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=FDA:葛兰素史克向欧盟提交Votrient新适应症申请, objectType=article, longId=22808, objectId=15c92280847, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=15c92280847, replyNumber=0, likeNumber=90, createdTime=2013-08-10, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=15c92280847, moduleTitle=FDA:葛兰素史克向欧盟提交Votrient新适应症申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=15c92280847)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336669, encodeId=c6121336669d8, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=安进Xgeva骨巨细胞瘤新适应症申请获FDA批准, objectType=article, longId=20856, objectId=2774208567b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2774208567b, replyNumber=0, likeNumber=65, createdTime=2013-07-05, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2774208567b, moduleTitle=安进Xgeva骨巨细胞瘤新适应症申请获FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2774208567b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336668, encodeId=6c5413366683d, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=FDA批准安进旗下狄诺塞麦骨巨细胞瘤新适应症, objectType=article, longId=20250, objectId=17e920250f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=17e920250f2, replyNumber=0, likeNumber=128, createdTime=2013-06-20, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=17e920250f2, moduleTitle=FDA批准安进旗下狄诺塞麦骨巨细胞瘤新适应症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=17e920250f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336667, encodeId=fd47133666e9d, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=FDA批准强生旗下戈利木单抗治疗溃疡性结肠炎新适应症, objectType=article, longId=19025, objectId=36c7190258f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36c7190258f, replyNumber=0, likeNumber=93, createdTime=2013-05-22, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36c7190258f, moduleTitle=FDA批准强生旗下戈利木单抗治疗溃疡性结肠炎新适应症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=36c7190258f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336666, encodeId=cce4133666625, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=EMA支持阿哌沙班用于房颤/卒中适应症, objectType=article, longId=10035, objectId=4a241003557, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a241003557, replyNumber=0, likeNumber=72, createdTime=2012-10-04, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a241003557, moduleTitle=EMA支持阿哌沙班用于房颤/卒中适应症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4a241003557)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336665, encodeId=486a1336665a7, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=FDA推迟雅培阿达木单抗(Humira)新适应症决定, objectType=article, longId=6480, objectId=12f9648099, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=12f9648099, replyNumber=0, likeNumber=65, createdTime=2012-05-26, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=12f9648099, moduleTitle=FDA推迟雅培阿达木单抗(Humira)新适应症决定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=12f9648099)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336664, encodeId=079d133666418, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=AAOS:金对金全髋关节置换失败情况及翻修适应症, objectType=article, longId=4768, objectId=bd3a4e68ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bd3a4e68ee, replyNumber=0, likeNumber=62, createdTime=2012-04-12, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bd3a4e68ee, moduleTitle=AAOS:金对金全髋关节置换失败情况及翻修适应症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bd3a4e68ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336663, encodeId=3a6013366636f, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=神经系统疾病营养支持适应症共识(2011版), objectType=article, longId=3396, objectId=59cd339631, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=59cd339631, replyNumber=0, likeNumber=86, createdTime=2011-12-06, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=59cd339631, moduleTitle=神经系统疾病营养支持适应症共识(2011版), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=59cd339631)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯话题小助手
关注
已关注
适应症
2020-05-29
644982816_68283321
(审核中...)
关注
已关注
前往app查看评论内容
#适应症#
强生抗癌药Imbruvica新适应症获FDA批准
65
0
2014-02-18
回复
644982816_68283321
(审核中...)
关注
已关注
前往app查看评论内容
#适应症#
强生拜瑞妥(Xarelto)ACS适应症遭FDA委员会否决
68
0
2014-01-19
回复
644982816_68283321
(审核中...)
关注
已关注
前往app查看评论内容
#适应症#
FDA对强生拜瑞妥(Xarelto)ACS适应症持谨慎态度
80
0
2014-01-18
回复
644982816_68283321
(审核中...)
关注
已关注
前往app查看评论内容
#适应症#
拜耳多吉美(Nexavar)新适应症用于分化型甲状腺癌获FDA批准
63
0
2013-11-27
回复
644982816_68283321
(审核中...)
关注
已关注
前往app查看评论内容
#适应症#
ACC/AHA 新胆固醇治疗指南被指扩大了他汀类药物的适应症人群
59
0
2013-11-21
回复
644982816_68283321
(审核中...)
关注
已关注
前往app查看评论内容
#适应症#
勃林格殷格翰向欧盟提交tiotropium Respimat®扩大适应症申请
59
0
2013-11-16
回复
644982816_68283321
(审核中...)
关注
已关注
前往app查看评论内容
#适应症#
FDA批准阿维莫泮用于术后加速恢复胃肠道功能的新适应症
67
0
2013-10-26
回复
644982816_68283321
(审核中...)
关注
已关注
前往app查看评论内容
#适应症#
葛兰素史克Revolade新适应症获欧盟批准
62
0
2013-09-28
回复
644982816_68283321
(审核中...)
关注
已关注
前往app查看评论内容
#适应症#
拜耳向EMA提交Stivarga治疗GIST新适应症申请
81
0
2013-09-11
回复
644982816_68283321
(审核中...)
关注
已关注
前往app查看评论内容
#适应症#
拜耳Eylea新适应症获欧盟批准
92
0
2013-09-01
回复
644982816_68283321
(审核中...)
关注
已关注
前往app查看评论内容
#适应症#
拜耳Stivarga新适应症获日本批准
69
0
2013-08-23
回复
644982816_68283321
(审核中...)
关注
已关注
前往app查看评论内容
#适应症#
葛兰素史克Tyberb新适应症获欧盟批准
72
0
2013-08-21
回复
644982816_68283321
(审核中...)
关注
已关注
前往app查看评论内容
#适应症#
FDA:葛兰素史克向欧盟提交Votrient新适应症申请
90
0
2013-08-10
回复
644982816_68283321
(审核中...)
关注
已关注
前往app查看评论内容
#适应症#
安进Xgeva骨巨细胞瘤新适应症申请获FDA批准
65
0
2013-07-05
回复
644982816_68283321
(审核中...)
关注
已关注
前往app查看评论内容
#适应症#
FDA批准安进旗下狄诺塞麦骨巨细胞瘤新适应症
128
0
2013-06-20
回复
644982816_68283321
(审核中...)
关注
已关注
前往app查看评论内容
#适应症#
FDA批准强生旗下戈利木单抗治疗溃疡性结肠炎新适应症
93
0
2013-05-22
回复
644982816_68283321
(审核中...)
关注
已关注
前往app查看评论内容
#适应症#
EMA支持阿哌沙班用于房颤/卒中适应症
72
0
2012-10-04
回复
644982816_68283321
(审核中...)
关注
已关注
前往app查看评论内容
#适应症#
FDA推迟雅培阿达木单抗(Humira)新适应症决定
65
0
2012-05-26
回复
644982816_68283321
(审核中...)
关注
已关注
前往app查看评论内容
#适应症#
AAOS:金对金全髋关节置换失败情况及翻修适应症
62
0
2012-04-12
回复
644982816_68283321
(审核中...)
关注
已关注
前往app查看评论内容
#适应症#
神经系统疾病营养支持适应症共识(2011版)
86
0
2011-12-06
回复
共220条
首页
上一页
下一页
尾页
页码:
11
/11页
20条/页
扫描二维码下载梅斯医学APP
科室
订阅+
更多科室
工具
服务